Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. “By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...

So, you want to invest in AbbVie (ABBV 2.33%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

Elahere secured full approval from the US Food and Drug Administration last year. Credit: © AbbVie. US-based pharmaceutical company AbbVie has reported the final ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...